nach oben

21.03.2024 | Acne inversa | CME

Hidradenitis suppurativa

verfasst von: Dr. med. M. Alter

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hidradenitis suppurativa (HS) ist eine chronisch-entzündliche Haut- und Systemerkrankung, die mit erheblichen Beschwerden und einer deutlichen Einschränkung der Lebensqualität einhergeht. Trotz rezent gestiegenem Verständnis für die Erkrankung wird die Diagnose weiterhin über viele Jahre verzögert gestellt. Durch den verzögerten Zugang der Patient:innen zu einer geeigneten Therapie kommt es oft zur Progression der Erkrankung mit vermehrten operativen Eingriffen und dem Auftreten von möglichen Komorbiditäten. In den letzten Jahren hat sich das Verständnis der Pathophysiologie der HS verbessert, und in der Folge wurden auch moderne Therapeutika für die HS zugelassen. Die Therapie der HS ruht auf 3 Säulen: Operation, Antibiotika und Biologika. Zudem sollten Risikofaktoren wie Rauchen und Adipositas positiv beeinflusst werden. Für die individualisierte Betreuung der Patienten ist die Kenntnis der Komorbiditäten und ihrer interdisziplinären Therapie von Bedeutung.

Zouboulis CC, Bechara FG, Fritz K, Kurzen H, Likakou AI, Marsch W, Milling A, Nast A, Podda M, Taube KM, Wienert V, Winkler T (2012) S1-Leitlinie zur Therapie der Hidradenitis suppurativa/Akne inversa (ICD-10 Ziffer L73.2). JDDG 10(Suppl 5):S1–S31PubMed

Sabat R, Tsaousi A, Rossbacher J, Kurzen H, Fadai T, Schwichtenberg U, Schneider-Burrus S (2017) Acne inversa/hidradenitis suppurativa: an update. Hautarzt 68(12):999–1006PubMedCrossRef

Jemec GBE (2012) Hidradenitis suppurativa. N Eng J Med 366(2):158–164CrossRef

Scholl L, Hessam S, Bergmann U, Bechara FG (2018) Surgical treatment of sinus tracts and Fistulas in Perianal Hidradenitis Suppurativa. J Cutan Med Surg 22(2):239–241PubMedCrossRef

Jemec GBE (2003) Hidradenitis suppurativa. J Cutan Med Surg 7:47–56PubMedCrossRef

Garg A, Papagermanos V, Midura M, Strunk A (2017) Incidence of hidradenitis suppurativa among tobacco smokers: a population based retrospective analysis in the U.S.A. Br J Dermatol

Ingram JR, Burton T (2017) NICE approval of adalimumab for moderate to-severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics? Br J Dermatol 176:281–282PubMedCrossRef

Wang 9. B, Yang W, Wen W, et al.: γ‑secretase gene mutations in familial acne inversa. Science 2010; 330: 1065

Kokolakis G, Wolk K, Schneider-Burrus S, Kalus S, Barbus S, Gomis-Kleindienst S, Sabat R (2020) Delayed diagnosis of hidradenitis supurativa and ist effect on patients and healthcare system. Dermatology 236(5):421–430PubMedCrossRef

10.

Kokolakis G (2020) Pain in Hidradenitis suppurativa: Data from the PIRANHA-Study. 9 EHSF-Konferenz; 05.–07. Athen, Griechenland

11.

Van der Zee HH, Laman JD, Boer J, Prens EP (2012) Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments. Exp Dermatol 21:735–739PubMedCrossRef

12.

Hessam S, Sand M, Gambichler T, Skrygan M, Rüddel I, Bechara FG (2018) Interleukin-36 in hidradenitis suppurativa: evidence for a distinctive proinflammatory role and a key factor in the development of an inflammatory loop. Br J Dermatol 178(3):761–767PubMedCrossRef

13.

Hessam S, Gambichler T, Skrygan M, Scholl L, Sand M, Meyer T, Stockfleth E, Bechara FG (2021) Increased expression profile of NCSTN, Notch and PI3K/AKT3 in hidradenitis suppurativa. J Eur Acad Dermatol Venereol 35(1):203–210PubMedCrossRef

14.

Kurzen H, Kurokawa I, Jemec GBE et al (2008) What causes hidradenitis suppurativa? Exp Dermatol 17:455–472PubMedCrossRef

15.

Zouboulis CC, del Marmol V, Mrowietz U, Prens E, Tzellos T, Jemec GBE (2015) Hidradenitis suppurativa/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology 231:184–190PubMedCrossRef

16.

Revuz JE, Canoui-Poitrine F, Wolkenstein P et al (2008) Prevalence and factors associated with hidradenitis suppurativa: results from two case control studies. J Am Acad Dermatol 59:596–601PubMedCrossRef

17.

Kromann CB, Ibler KS, Kristiansen VB, Jemec GBE (2014) The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol 94:553–557PubMedCrossRef

18.

Just E, Winkler T (2021) Acne inversa: eine seltene Erkrankung mit weitreichenden Auswirkungen für Betroffene: Erfahrungen und Wünsche von Patienten [Acne inversa: A rare disease with far-reaching consequences for those affected : Experiences and wishes of patients. Hautarzt 72(8):715–718PubMedCrossRef

19.

Alikhan A, Lynch PJ, Eisen DB (2009) Hidradenitis suppurativa: a comprehensive review. JAAD 60(4):539–561PubMedCrossRef

20.

Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhász I, Lapins J, Matusiak L, Prens EP, Revuz EP, Schneider-Burrus S, Szepietowski JC, Van der Zee HH, Jemec GBE (2015) European S1 guidline for the treatment of hidradenitis suppurativa/acne inversa. JEADV 29(4):619–644PubMed

21.

Ingram JR, Porter M, Chovatiya R et al (2023) Bimekizumab Response Maintenance to 48 Weeks in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Responder Analysis from the Phase 3, Double-blind, Placebo-Controlled, Randomised Clinical Trials BE HEARD I and II. EADV (Poster P0086)

22.

Kimball AB et al (2020) irtuelle Jahrestagung der American Acacemy of Dermatology (AAD). v (Poster # P16480)

23.

Zouboulis CC, Tzellos T, Kyrgidis A, Jemec GBE, Bechara FG, Giamarellos-bourboulis EJ, Ingram JR, Kanni T, Karagianniis I, Martorell A, Matusiak Ł, Pinter A, Prens EP, Presser D, Achneider-Burrus S, von Stebut E, Szepietowski JC, van der Zee HH, Wilden SM, Sabat R, European Hidradenitits Suppurativa Foundation Investigator Group, Vekic D, de Haes P, del Marmol V, Alavi A, Gulliver W, Nassif A, Nikolakis G, Podda M, Antoniou C, Delli FS, Dessinioti C, Patsatsi A, Trigoni AP, Zisimou C, Bettoli V, Garcovich S, Boer J, Horváth B, Ingvarsson G, Puig L, Hunger RE, Emtestam L, Danby FW, Kimball AB (2017) Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol 177(5):1401–1409PubMedCrossRef

24.

Hessam S, Scholl L, Sand M, Schmitz L, Reitenbach S, Bechara FG (2018) A novel severity assessment scoring system for hidradenitis suppurativa. JAMA Dermatol 154(3):330–335. https://doi.org/10.1001/jamadermatol.2017.5890CrossRefPubMedPubMedCentral

25.

Horváth B, Janse IC, Blok JL, Driessen RJB, Boer J, Mekkes JR, Prens EP, van der Zee HH (2017) Hurley staging refined: a proposal by the Dutchhidradenitis suppurativa expert group. Acta Derm Venereol 97(3):412–413PubMedCrossRef

26.

Sabat R, Jemec GBE, Matusiak Ł, Kimball AB, Prens E, Wolk K (2020) Hidradenitis suppurativa. Nat Rev Dis Primers 6(1):18PubMedCrossRef

27.

Ocker L, Abu Rached N, Seifert C, Scheel C, Bechara FG (2022) Current medical and surgical treatment of hidradenitis suppurativa—a comprehensive review. J Clin Med 11(23):7240PubMedPubMedCentralCrossRef

28.

Bechara FG, Podda M, Prens EP et al (2021) Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial. JAMA Surg 156:1001–1009PubMedCrossRef

29.

Aarts P, van Huijstee JC, van der Zee HH, van Doorn MBA, van Straalen KR, Prens EP (2023) Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: a randomized controlled trial in a real-world setting. J Am Acad Dermatol 89(4):677–684PubMedCrossRef

30.

Scholl L, Schneider-Burrus S, Fritz B, Sabat R, Bechara FG (2023) Auswirkungen chirurgischer Eingriffe auf das psychosoziale Wohlbefinden von Patienten mit Hidradenitis suppura. JDDG 21:131–140PubMed

31.

Goldburg SR, Strober BE, Payette MJ (2020) Hidradenitis suppurativa: current and emerging treatments. J Am Acad Dermatol 82(5):1061–1082PubMedCrossRef

32.

Orenstein LAV, Nguyen TV, Damiani G, Sayed C, Jemec GB, Hamzav I (2020) Medical and surgical management of hidradenitis suppurativa: a review of international treatment guidelines and implementation in general dermatology practice. Dermatology 236(5):393–412PubMedCrossRef

33.

Cramer P, Schneider-Burrus S, Kovács M, Scholl L, Podda M, Bechara FG (2021) Hidradenitis suppurativa/acne inversa-surgical options, reconstruction and combinations with drug therapies—an update. Hautarzt 72(8):692–699PubMedPubMedCentralCrossRef

34.

DeFazio MV, Economides JM, King KS, Han KD, Shanmugam VK, Attinger CE, Evans KK (2016) Outcomes after combined radical resection and targeted biologic therapy for the management of recalcitrant hidradenitis suppurativa. Ann Plast Surg 77(2):217–222PubMedPubMedCentralCrossRef

35.

Mehdizadeh A, Hazen PG, Bechara FG, Zwingerman N, Moazenzadeh M, Bashash M, Sibbald RG, Alavi A (2015) Recurrence of hidradenitis suppurativa after surgical management: a systematic review and meta-analysis. J Am Acad Dermatol 73(5 Suppl 1):S70–S77PubMedCrossRef

36.

Jemec GB, Wendelboe P (1998) Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol 39:971–974PubMedCrossRef

37.

van Straalen KR, Tzellos T, Guillem P et al (2021) The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: results of a prospective European cohort study. J Am Acad Dermatol 85:369–378PubMedCrossRef

38.

van Straalen KR, Tzellos T, Guillem P, Benhadou F, Cuenca-Barrales C, Daxhelet M, Daoud M, Efthymiou O, Giamarellos-Bourboulis EJ, Jemec GBE, Katoulis AC, Koenig A, Lazaridou E, Marzano AV, Matusiak Ł, Molina-Leyva A, Moltrasio C, Pinter A, Potenza C, Romaní J, Saunte DM, Skroza N, Stergianou D, Szepietowski J, Trigoni A, Vilarrasa E, van der Zee HH (2021) The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: results of a prospective European cohort study. J Am Acad Dermatol 85(2):369–378PubMedCrossRef

39.

Bettoli V, Manfredini M, Massoli L et al (2019) Rates of antibiotic resistance/sensitivity in bacterial cultures of hidradenitis suppurativa patients. J Eur Acad Dermatol Venereol 33:930–936PubMedCrossRef

40.

Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, Armstrong AW, Kerdel F, Gold MH, Forman SB, Korman NJ, Giamarellos-Bourboulis EJ, Crowley JJ, Lynde C, Reguiai Z, Prens EP, Alwawi E, Mostafa NM, Pinsky B, Sundaram M, Gu Y, Carlson DM, Jemec GB (2016) Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med 375(5):422–434PubMedCrossRef

41.

Hotz C, Boniotto M, Guguin A, Surenaud M, Jean-Louis F, Tisserand P, Ortonne N, Hersant B, Bosc R, Poli F, Bonnabau H, Thiébaut R, Godot V, Wolkenstein P, Hocini H, Lévy Y, Hüe S (2016) Intrinsic defect in keratinocyte function leads to inflammation in hidradenitis suppurativa. J Invest Dermatol 136(9):1768–1780PubMedCrossRef

42.

Moran B, Sweeney CM, Hughes R, Malara A, Kirthi S, Tobin AM, Kirby B, Fletcher JM (2017) Hidradenitis suppurativa is characterized by dysregulation of the Th17:treg cell axis, which is corrected by anti-TNF therapy. J Invest Dermatol 137(11):2389–2395PubMedCrossRef

43.

Matusiak Ł, Szczęch J, Bieniek A, Nowicka-Suszko D, Szepietowski JC (2017) Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents. J Am Acad Dermatol 76(4):670–675PubMedCrossRef

44.

Kimball AB, Loesche C, Prens EP, Bechara FG, Weisman J, Rozenberg I, Jarvis P, Peters T, Roth L, Wieczorek G, Kolbinger F, Jemec GBE (2022) IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: combined results from a pre-clinical and phase II proof-of-concept study. Exp Dermatol 31(10):1522–1532PubMedPubMedCentralCrossRef

45.

Melgosa Ramos FJ, García-Ruiz R, Gegúndez Hernández H, Mateu-Puchades A (2023) Real-life experience of secukinumab in patients with hidradenitis suppurativa. Actas Dermosifiliogr 114(4):360–362PubMedCrossRef

46.

Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, Paul C, Giamarellos Bourboulis EJ, Villani AP, Schwinn A, Ruëff F, Pillay Ramaya L, Reich A, Lobo I, Sinclair R, Passeron T, Martorell A, Mendes-Bastos P, Kokolakis G, Becherel PA, Wozniak MB, Martinez AL, Wei X, Uhlmann L, Passera A, Keefe D, Martin R, Field C, Chen L, Vandemeulebroecke M, Ravichandran S, Muscianisi E (2023) Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet 401(10378):747–761PubMedCrossRef

47.

Glatt S, Jemec GBE, Forman S et al (2021) Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial. JAMA Dermatol 157:1279–1288PubMedCrossRef

48.

Zouboulis CC et al (2023) Bimekizumab efficacy and safety in patients with moderate to severe hidradenitis suppurativa: analysis of pooled data from BE HEARD I and II phase 3, randomised, double-blind, placebo-controlled, multicentre studies. EADV. Oral Presentation, S 3262

49.

Zouboulis CC et al (2023) IHS4 outcomes with bimekizumab in patients with moderate to severe hidradenitis suppurativa: pooled results from the BE HEARD I and II phase 3 trials. EADV. Oral Presentation, S 3512

50.

Bechara FG, Hamzavi I, Anadkat MJ et al (2023) Bimekizumab safety in patients with moderate to severe hidradenitis suppurativa: analysis of pooled data from the BE HEARD I and II phase 3, randomised, double-blind, placebo-controlled, multicentre studies. EADV (Poster P0087)

51.

Kirby JS, Okun MM, Alavi A, Bechara FG, Zouboulis CC, Brown K, Santos LL, Wang A, Bibeau KB, Kimball AB, Porter ML (2023) Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study. J Am Acad Dermatol

52.

Steenholdt C (2016) Personalized therapy with TNF-inhibitors in crohn’s disease: optimizing treatment outcomes by monitoring drug levels and anti-drug antibodies. Dan Med J 63(8):B5270PubMed

53.

van der Zee HH, de Ruiter L, van den Broecke DG, Dik WA, Laman JD, Prens EP (2011) Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF‑α and IL-1β. Br J Dermatol 164(6):1292–1298PubMedCrossRef

54.

Gambichler T, Hessam S, Cramer P, Abu Rached N, Bechara FG (2022) Complete blood collection-based systemic inflammation biomarkers for patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 36(9):1593–1596PubMedCrossRef

55.

Hessam S, Sand M, Gambichler T, Bechara FG (2015) Correlation of inflammatory serum markers with disease severity in patients with hidradenitis suppurativa (HS). J Am Acad Dermatol 73(6):998–1005PubMedCrossRef

56.

Garg A, Hundal J, Strunk A (2018) Overall and subgroup prevalence of crohn disease among patients with hidradenitis suppurativa: a population-based analysis in the United States. JAMA Dermatol 154(7):814–818PubMedPubMedCentralCrossRef

57.

Phan K, Charlton O, Smith SD (2019) Hidradenitis suppurativa and metabolic syndrome—systematic review and adjusted meta-analysis. Int J Dermatol 58(10):1112–1117PubMedCrossRef

58.

Richette P, Molto A, Viguier M, Dawidowicz K, Hayem G, Nassif A, Wendling D, Aubin F, Lioté F, Bachelez H (2014) Hidradenitis suppurativa associated with spondyloarthritis—results from a multicenter national prospective study. J Rheumatol 41(3):490–494PubMedCrossRef

59.

Schneider-Burrus S, Witte-Haendel E, Christou D, Rigoni B, Sabat R, Diederichs G (2016) High prevalence of back pain and axial spondyloarthropathy in patients with hidradenitis suppurativa. Dermatology 232(5):606–612PubMedCrossRef

60.

Wertenteil S, Strunk A, Garg A (2019) Overall and subgroup prevalence of acne vulgaris among patients with hidradenitis suppurativa. J Am Acad Dermatol 80(5):e131–e132PubMedCrossRef

61.

Kridin K, Shani M, Schonmann Y, Fisher S, Shalom G, Comaneshter D, Batat E, Cohen AD (2023) Psoriasis and hidradenitis suppurativa: a large-scale population-based study. J Am Acad Dermatol 88(5):e231–e236PubMedCrossRef

62.

Kirsten N, Zander N, Augustin M (2021) Prevalence and cutaneous comorbidities of hidradenitis suppurativa in the German working population. Arch Dermatol Res 313(2):95–99PubMedCrossRef

63.

Sabat R, Chanwangpong A, Schneider-Burrus S, Metternich D, Kokolakis G, Kurek A, Philipp S, Uribe D, Wolk K, Sterry W (2012) Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One 7(2):e31810ADSPubMedPubMedCentralCrossRef

64.

Miller IM, Ellervik C, Vinding GR, Zarchi K, Ibler KS, Knudsen KM, Jemec GB (2014) Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol 150(12):1273–1280PubMedCrossRef

65.

Egeberg A, Gislason GH, Hansen PR (2016) Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa. JAMA Dermatol 152(4):429–434PubMedCrossRef

66.

Gold DA, Reeder VJ, Mahan MG, Hamzavi IH (2014) The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. J Am Acad Dermatol 70(4):699–703PubMedCrossRef

67.

Kohorst JJ, Kimball AB, Davis MD (2015) Systemic associations of hidradenitis suppurativa. J Am Acad Dermatol 73(5 Suppl 1):S27–35PubMedCrossRef

68.

Abu Rached N, Gambichler T, Ocker L, Dietrich JW, Quast DR, Sieger C, Seifert C, Scheel C, Bechara FG (2023) Screening for diabetes mellitus in patients with hidradenitis suppurativa—a monocentric study in Germany. Int J Mol Sci 24(7):6596PubMedPubMedCentralCrossRef

69.

Tiri H, Jokelainen J, Timonen M, Tasanen K, Huilaja L (2019) Substantially reduced life expectancy in patients with hidradenitis suppurativa: a finnish nationwide registry study. Br J Dermatol 180(6):1543–1544PubMedCrossRef

70.

Kirsten N, Frings V, Nikolakis GD, Presser D, Goebeler M, Zouboulis CC, Augustin M (2021) Epidemiology, patient quality of life, and treatment costs of hidradenitis suppurativa/acne inversa. Hautarzt 72(8):651–657PubMedCrossRef

71.

Pinter A, Kokolakis G, Rech J, Biermann MHC, Häberle BM, Multimeier J, Reinhardt M (2020) Hidradenitis suppurativa and concurrent psoriasis: comparison of epidemiologiy, comorbidity profiles, and risk factors. Dermatol Ther (Heidelb) 10(4):721–734PubMedCrossRef

Titel: Hidradenitis suppurativa
verfasst von: Dr. med. M. Alter
Publikationsdatum: 21.03.2024
Verlag: Springer Medizin
Schlagwörter: Acne inversa
Antibiotika
Erschienen in: Die Dermatologie
Print ISSN: 2731-7005
Elektronische ISSN: 2731-7013
DOI: https://doi.org/10.1007/s00105-024-05321-y

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

08.05.2024 Akne Nachrichten

Die Aknetherapie mit Isotretinoin kann einen Anstieg von Leberenzymen und Blutfetten verursachen. Das Risiko für schwere Störungen ist laut einer Forschungsgruppe der Universität Lübeck aber nur marginal erhöht und auf einen engen Zeitraum konzentriert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen